Providing Pharmacy Services during the Coronavirus Pandemic in the KSA

Nouf Abdulfatah Hajeeb^{1*}, Rayan mohammed jomah²

1* Corresponding Author, Technician-pharmacy, Dept. of Pharmacy, KFMC, Riyadh, SA

2 Technician-pharmacy, Dept. of Pharmacy, KFMC, Riyadh, SA

DOI: https://doi.org/10.5281/zenodo.7981019

Published Date: 29-May-2023

Abstract: Coronavirus disease 19 (COVID-19) is spreading rapidly in China and around the world. Pharmacy services are an important public health pillar to prevent and contain the COVID-19 pandemic. Saudi pharmacists have acted quickly in public relations work in KSA, such as: B. Developing a professional services guide for pharmacists and pharmacies, creating emergency medication forms, monitoring and resolving drug shortages, setting up remote pharmacy services to treat human infections prevent human, provide event-based pharmaceutical care, educate the public about infection prevention and infection management, diseases, and participate in clinical trials and drug evaluation. This comment addresses the unique needs of pharmacy services in the COVID-19 pandemic and shares our experiences with the international pharmaceutical community in the response to meet these requirements.

Keywords: China, KSA, Coronavirus, COVID-19, Pharmaceutical care, Pharmacists, Pharmacy service, Public health.

Impacts on practice

- Countries should establish or strengthen pharmacy sup- port services in combating the coronavirus pandemic.
- Pharmacists should identify and serve the unique needs of pharmacy services in a pandemic.
- Focused actions such as establishing remote pharmacy services to prevent the transmission of the coronavirus should be considered.

• National emergency drug formularies should be created and pharmacists should monitor and resolve potential drug shortages associated with a pandemic.

1. INTRODUCTION

An outbreak of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome cor-onavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019 [1]. The genetic characteristics of SARS-CoV-2 have proven to be significantly different from human SARS CoV and Middle Eastern respiratory syn-drome (MERS) CoV [2]. Common signs of SARS-CoV-2 infection include respiratory symptoms, fever, cough, short-ness of breath, and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, organ failure and even death [1]. The virus is highly infectious, spreading rapidly via human-to-humantransmission. As of March 12, 2020, there were 80,981 con-firmed cases in China (3173 deaths) and 44,067 cases in 117 countries/territories/areas outside China (1440 deaths)

[3]. Currently there are no approved antiviral therapies for COVID-19. The World Health Organization (WHO) has now declared the coronavirus a global pandemic.

Vol. 11, Issue 1, pp: (32-38), Month: April 2023 - September 2023, Available at: www.researchpublish.com

When responding to the COVID-19 pandemic, medical services are under great pressure. An effective coordinated pharmacy support system and event-driven pharmaceuti- cal care activities are needed. Mobile cabin hospitals, the "Square Cabin Hospitals" have been built in Wuhan, China(the epidemic epicenter in China) to treat patients with mildsymptoms of the virus. Pharmacists are actively engaging

in the public health operation in KSA since the outbreak, either at their home hospitals and community pharmacies or at the square cabin hospitals in Wuhan. The Saudi phar- macy profession has gained valuable experiences through providing essential support to the public health operation. In this commentary, we share our experiences of providing pharmacy services combating coronavirus in KSA to dis- seminate what we have learned to the international phar- macy society.

2. THE UNIQUE NEEDS OF PHARMACY SERVICES DURING THIS CORONAVIRUS PANDEMIC

The timely supply of preventive and treatment medications, and the provision of event-driven pharmaceutical care are critical to support and enhance public health emergency operations during the coronavirus pandemic. Specifically, pharmacy needs to work with other healthcare organizations, professionals, and government agencies to address the fol- lowing seven service needs: (1) drafting professional service guidances to pharmacists and pharmacies, (2) establishing emergency drug formularies based on treatment guidelines,

(3) coordinating with drug companies and distributors to ensure adequate supply, storage and transport of identified formulary drugs, (4) providing event-driven pharmaceuticalcare, (5) establishing remote pharmacy services to reduce the incidence of human-to-human infections, (6) educating the public with a focus on infection prevention and disease management, and (7) involving in clinical trial research to screen, evaluate and develop antiviral medications in line with national and international guidelines [4]. Additionally, pharmacists must learn how to protect themselves from get-ting infected as well. In the next section, we share the phar-macy's responses in meeting the needs of pharmacy services Saudi during the epidemic.

3. PHARMACY RESPONSES TO COMBAT THE CORONAVIRUS EPIDEMIC IN KSA

Response 1: Draft professional service guidance to pharmacists and pharmacies

To outline the roles that pharmacists in community, hospital and other diverse healthcare settings can play in prevent- ing the spread of COVID-19 and supporting the efficient management of infection by healthcare systems,

The Department of Pharmacy at King Fahad Medical City in KSA, proposed to develop a "pharmacy emergency support guarantee system" within a public health response operation, a novel initiative in Saudi pub- lic health (Fig. 1). The pharmacy system aims to establish mechanisms to address drug shortages through surveillance, early warnings, drug emergency supply and distribution, monitoring the safe use of medications, and event-driven pharmaceutical care during the coronavirus epidemic [4].

Response 2: Establish emergency drug formularies based on treatment guidelines

There is currently no specific vaccine and no effective antivi- ral therapy against SARS-CoV-2. The China National Health Commission (CNHC) has released the "Diagnosis and Treat-ment Guidelines for the New Coronavirus Infected Pneumo-nia" (the CNHC guidelines), currently in its sixth update [8]. The CNHC guidelines suggest the use of antiviral drugs (α -interferon, lopinavir/ritonavir, ribavirin, chloroquine, umifenovir) and traditional Chinese medicines (TCMs) for treatment. Although these therapies may not be recom- mended by the WHO, their treatment roles are based on past experiences during the SARS outbreak in China in 2003 with the consideration of lack of drug therapies to treat the coronavirus. The CNHC guidelines recommend eight TCM injections for severe and critical cases. For severe cases, *Xiyanping, Xuebijing, Reduning, Tanreqing* and *Xingnaojing* injections are recommended. For critical cases, three addi- tional TCM injections can be considered, *Shenfu, Shengmai* and *Shenmai*.

To assist clinicians in better understanding and prescrib-ing these drugs, pharmacists applied evidence-based medi- cation use evaluation approaches to collect and summarize

Vol. 11, Issue 1, pp: (32-38), Month: April 2023 - September 2023, Available at: www.researchpublish.com




Fig. 1 Pharmacy emergency support guarantee system within a public health response

drug information with these recommended drugs. The Hunan Pharmaceutical Association and the Chinese Hospi-tal Association Pharmaceutical Committee each separately compiled the "Drug Information for the Diagnosis and Treatment of New Coronavirus Pneumonia" and the "DrugFormulary in Square Cabin Hospitals".

Response 3: Monitor and resolve drug shortages

During the coronavirus pandemic, both prescription (includ-ing resuscitation drugs) and over-the-counter (OTC) medica-tion shortages may occur. Drugs may also be in short supplydue to production disruptions for various reasons. Pharma- cists and pharmacies must conduct active surveillance and establish early warning mechanisms to address drug short- ages in a timely manner. The American Society of Health- System Pharmacists (ASHP) guidelines on managing drug product shortages and a published provincial drug shortage surveillance and early warning platform in Hunan, China, can be referenced and adapted to create local, regional and national platforms to manage prescription drug shortages during a pandemic [9, 10]. Figure 2 shows the proposed prescription drug shortage surveillance and early warning mechanism. Community pharmacies and pharmacists should

pay equal attention to potential shortages of OTC drugs. This is especially important due to an increase in the publicbuying OTCs to treat the symptoms of the illness (fever, cough and shortness of breath) from the advice of healthcareprofessionals and public agencies.

Response 4: Provide event-driven pharmaceutical care activities

Event-driven pharmaceutical care is provided to COVID- 19 patients in China during the epidemic. The event-driven pharmaceutical care goes beyond routine activities (medi- cation review, prescribing support and patient counseling). Three characteristics of the event-driven pharmaceutical careare (1) ensuring the appropriate use of off-label drugs: manydrugs recommended in the CNHC guidelines are used off- label. Pharmacists conduct literature evaluations and publishguidances for the off-label use of these drugs. Adverse drugreactions of some of these drugs are similar to the symptoms of the coronavirus disease (such as fatigue, fever, and flu-like symptoms with α -interferon). It is necessary for pharmaciststo assist in evaluating the efficacy and safety of these drugsand to monitor adverse drug reactions. The pathological anatomy of the first patient with a COVID-19 related death.

Vol. 11, Issue 1, pp: (32-38), Month: April 2023 - September 2023, Available at: www.researchpublish.com




Fig. 2 A drug shortage surveillance and early warning mechanism in a pharmacy emergency support guarantee system

showed liver damage [11], which was either drug-induced or caused by the SARS-CoV-2. Pharmacists are reminded to monitor drugs that may cause liver damage and to adjustdrug dosing based on the patient's liver function, (2) ensur-ing the rational use of TCMs: the CNHC guidelines recom-mend the use of TCMs for the coronavirus treatment. Pre- liminary evidence shows that integrating TCMs and Westernmedicines for COVID-19 can improve the clinical cure rateand reduce the rate of disease progression from common infection type to severe type [12]. However, it is worth not-ing that the current research of TCMs is based on clinical observations and is mostly used for patients with mild symp-toms. Pharmacists with specialized training in TCM are con-fronted with preparing TCM formulations, providing drug information to physicians, and TCM pharmaceutical care for patients. Pharmacists should warn physicians about any interactions between TCMs and Western medicines when these drugs are prescribed. For example, the combination of *Hanshi Yufei* decoction and antipyretic analgesics can cause excessive sweating and even dehydration. Some proprietary TCMs contain Western medicine ingredients, such as *Pipa Lu*, a strong antitussive, contains 0.15 mg of morphine per milliliter. Serotonin syndrome may occur when *Pipa Lu* is administered with monoamine oxidase inhibitors such as linezolid, and (3) providing online real-

time clinical sup- port to frontline physicians and pharmacists working at the epidemic epi-center: Wechat[®] (the largest social commu- nication mobile platform in China) groups are established

by pharmacy experts and pharmacists in China to provide clinical support for front-line pharmacists in Hubei, the epi-center of the coronavirus outbreak. These chat groups create accessible drug use platforms by engaging in phar- macotherapy consultation through information and resourcesharing in real-time.

Response 5: Establish remote pharmacy services to reduce human-to-human infections

In order to effectively reduce overcrowding and block the spread of the virus through person-to-person transmis- sion during the coronavirus epidemic, medical institutions across China have launched remote pharmacy services suchas online drug prescribing, drug consultation, and drugdelivery services. For example, the Pharmacy Department of Xiangya

Hospital, Central South University, created an online remote pharmacy service via WeChat[®]. Pharmacistsprovide patients with free medication consultation and edu-cation, allowing patients to purchase medications online and arrange for home drug delivery. The implementation of these remote pharmacy services provides out-of-hospitalpharmaceutical care access and helps to reduce the risk of cross-infection during unnecessary hospital visits. The posi-tive effects of these remote services on patient care during the epidemic is helpful for pharmacy to further establish itsprofessional role in China.

Vol. 11, Issue 1, pp: (32-38), Month: April 2023 - September 2023, Available at: www.researchpublish.com

Response 6: Educate the public with a focus on infection prevention and disease management

During an epidemic, false information and rumors can generate serious negative effects when the public cannot access timely, authoritative, and scientific information regarding the epidemic [13]. For example, after the media in China reported that Shuanghuanglian, a TCM that con- tains extracts from the dried fruit of Forsythiae fructus, inhibits SARS-CoV-2 in vitro, it sparked panic buying of this medication online and offline. The mass of people assembling to purchase this oral solution increased the risk of human-to-human disease transmission. Similarly, after the media reported that chloroquine phosphate can inhibit SARS-CoV-2 in vitro, there were reports of a female patientwho was not infected with SARS-CoV-2 but self-medicated with hydroxychloroquine sulfate tablets (1.8 g, 24 h). The patient subsequently developed mental disorders and cardiacarrhythmias requiring hospitalization in an intensive care unit. These incidences demonstrate that it is necessary for pharmacists and pharmacy associations to engage in publiceducation to disseminate reliable authoritative information to the public and guide the public's rational thinking and behavior during the coronavirus epidemic. To this end, the Chinese Pharmacists Association and the Chinese Pharma- cological Society released the "Expert Consensus Guidance on the Rational Drug Administration and Home Drug Ther-apy during an Epidemic" [14]. A large number of popular science articles on coronavirus infection prevention and treatment and on home medication use during an epidemic have been written by pharmacists and published over the internet with the hope of decreasing drug-related problems. The need to provide education to particular population sub-groups (homeless, prisoners, etc.) should be addressed. It isimportant to note that the impact of these public education activities depends on the public trust of pharmacists and pharmacy as a profession.

Response 7: Participate in clinical trials and drug evaluation

Currently, more than 80 clinical trials have been regis-tered in the Chinese Clinical Registry to test for a corona- virus treatment. During the first week of February, China launched two placebo-controlled trials of remdesivir, slatedto include 760 people with COVID-19. The studies should be completed by the end of April, 2020. A few trials have started to test chloroquine, an antimalarial drug that killed off the SARS-CoV-2 in cell cultures. Researchers are study-ing whether steroids diminish inflammation in people with severe COVID-19, or cause harm. Another 300-person con-trolled trial is aimed to test whether serum antibodies from COVID-19 survivors could rapidly help someone newly

infected with the SARS-CoV-2 virus. Fifteen trials listed inChina's registry expect to enroll a total of more than 2,000 people in studies on a variety of TCMs, including the largesttrial assessing *Shuanghuanglian* with 400 participants [15]. Pharmacists are actively cooperating with research spon- sors in the management of clinical trials including the proper supply, use, storage and disposal of experimental drugs in compliance with relevant clinical trial regulations. Pharma-cists are also actively conducting pharmaceutical evaluations on the efficacy and safety of related trial drugs.

In summary, during the coronavirus epidemic in China, the Chinese pharmacy profession has acted swiftly and forcefully with the above seven responses. The impact of these measures needs to be further evaluated, especially theseveral responses that rely on the public trust of pharmacy as a profession in China.

4. FUTURE EFFORTS OF PHARMACY SERVICES IN THE CORONAVIRUS EPIDEMIC

The epidemic of COVID-19 is quickly evolving, and the prevention and treatment pose great challenges to pharmacy services. Although Chinese pharmacists have made signifi-cant contributions to the public health operation in fight- ing the epidemic, the epidemic exposes a series of threats that we should face directly. The first is that the number of frontline pharmacists is inadequate. For example, there are nearly 1000 beds in a square cabin hospital, equipped with nearly 200 drugs, including antiviral drugs, rescue drugs, and drugs used in the respiratory, digestive and cardiovas- cular systems. However, only three to five pharmacists are stationed at each square cabin hospital. Pharmacists are undertaking dual responsibilities in the process of drug sup-ply and management, and pharmaceutical care. It is not pos-sible for a pharmacist to be able to provide quality, essential pharmacy services with these heavy workloads. Second, the lack of pharmacist consultations can lead to an overutili- zation and inappropriate use of antibacterial medications. Some doctors routinely prescribe COVID-19 patients anti- biotics such as quinolones or cephalosporins in the absence of a diagnosed bacterial infection. This prescribing behav- ior increases the risk of microbial resistance and adverse reactions. Third, most research manuscripts related to the coronavirus pharmacy services were written in Chinese and published in Chinese journals, thus they cannot easily be shared with the international pharmacy community. Fourth, although many drugs are being studied in clinical trials, thedesign and quality of these clinical trials should be prop-erly monitored. Many trials contain levels of bias such as small sample size and lack of control, randomization, and objective outcome evaluation criteria. As a result, these clinical trials are wasting valuable resources, and will be

Vol. 11, Issue 1, pp: (32-38), Month: April 2023 - September 2023, Available at: www.researchpublish.com

unable to provide high-quality evidence of treatment efficacyand safety. In response, the China State Council issued the "Notice on Standardizing Medical Institutions to Conduct Clinical Research on New Coronavirus Pneumonia Drug Therapy" [16]. The notice aimed to screen more effective drugs through standardized, scientific, orderly, and efficientclinical drug research. The first point is to further clarify the conditions for conducting research. For example, the drugs used for clinical research should be a marketed drug that has been validated by in vitro and animal experiments. Thesecond point is to further standardize the research process with regards to ethical review and record-keeping, and hos-pitals should perform quality control and risk management throughout the process. The third point is to speed up the application in an orderly manner. For example, the scien- tific research group recommends experimental drugs to the joint prevention and control medical treatment group, and the medical treatment group decides whether to expand thescope of their use or include them in the treatment plan.

Two final reflections: professional guidances should be established not only to pharmacists and pharmacies but alsoto the general population and to particular population sub- groups (e.g. homeless, prisoners, etc.). The role of the com-munity pharmacists in preventing the spread of COVID-19 virus should be strengthened. Community pharmacists are charged with key responsibilities including informing, advis- ing, and educating the community; maintaining a stable sup- ply of pharmaceuticals and personal hygiene products; and screening suspected cases and making appropriate referralsas necessary [17].

In summary, Chinese pharmacists and pharmacy associa-tions have responded forcefully to the COVID-19 epidemic. The experiences and lessons learned in China not only allow the Chinese pharmacy profession to improve pharmacy oper-ations, but also provide insight to the international pharmacycommunity to plan and operate pharmacy services to combatcurrent and future epidemics.

Acknowledgements Authors would like to thank the department of pharmacy in KFMC for their support.

Funding None.

Conflicts of interest: The authors declare that they have no conflict of interest.

REFERENCES

- [1] Han Q, Lin Q, Jin S, You L. Recent insights into 2019-nCoV: a brief but comprehensive review. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.02.010(Epub ahead to print).
- [2] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N EnglJ Med. 2020;382:727–33.
- [3] WHO Coronavirus Disease 2019 (COVID-19) Situation Report-52. https://www.who.int/docs/default-source/coron aviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2. Accessed 12 Mar 2020.
- [4] Liu S, He G, Du J, Wang D, Shi C, Huang Q, et al. Pharmaceutical emergency guarantee difficulties and countermeasures for the pre-vention and control of outbreak of novel coronavirus pneumonia (NCP). Chin J Hosp Pharm. 2020; 40(3):243–9.
- [5] The Chinese Pharmaceutical Association. The coronavirus SARS-CoV-2 infection: expert consensus on hospital pharmaceutical work guidance and prevention and control strategies. https://www.cpa.org.cn/cpadmn/attached/file/ 20200216/158185296047317 7.pdf. Accessed 12 Mar 2020.
- [6] The Chinese Pharmaceutical Association. The coronavirus SARS-CoV-2 infection: expert consensus on work guidance and preven-tion and control strategies for retail pharmacies. https://www.cpa.org.cn/cpadmn/attached/file/20200210/ 1581311477105875.pdf. Accessed 12 Mar 2020.
- [7] International Pharmaceutical Federation (FIP). SRAS-CoV-2 out-break preparedness. https://www.fip.org/coronavirus. Accessed 11Mar 2020.
- [8] China National Health Commission. Diagnosis and treatment guidelines for the new coronavirus infected pneumonia. https://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df3 51d7da8aefc2/files/b218cfeb1bc54639af227 f922bf6b817.pdf. Accessed 12 Mar 2020.
- [9] Fox ER, McLaughlin MM. ASHP guidelines on manag-ing drug product shortages. Am J Health Syst Pharm. 2018;75(21):1742–50.

Vol. 11, Issue 1, pp: (32-38), Month: April 2023 - September 2023, Available at: www.researchpublish.com

- [10] Shi Y, Yang P, Li X, Lv J, Yin T, Gong Z. Combating drug short-ages in China: surveillance warning and practice standardization.Int J Clin Pharm. 2020. https://doi.org/10.1007/s11096-020-00987-5 (Epub ahead of print).
- [11] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Patholog- ical findings of COVID-19 associated with acute respiratory dis-tress syndrome. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30076-X (Epub ahead of print).
- [12] Wang ZF, Wang YP, Zhang HM, Fan YP, Lü C, Wang YY. Think-ing on clinical rational use of TCM injection in the treatment of novel coronavirus pneumonia (COVID-19). Zhonghua Yi Xue ZaZhi. 2020;100:E016. https://doi.org/ 10.3760/cma.j.issn.cn112137- 20200221-00388 (Epub ahead of print).
- [13] Lancet T. COVID-19: fighting panic with information. Lan- cet. 2020;395(10224):537. https://doi.org/10.1016/ S0140-6736(20)30379-2.
- [14] Expert consensus guidance on the rational drug administration and home drug therapy during an epidemic. https://www.tdmch ina.org/portal.php?mod=view&aid=627. Accessed 12 Mar 2020.
- [15] Maxmen A. Slew of trials launch to test coronavirus treatments in China. Nature. 2020;578:347-8.
- [16] China State Council. Notice on standardizing medical institutions to conduct clinical research on new coronavirus pneumonia drugtherapy. https://www.gov.cn/xinwen/2020-02/26/content_54834 29.htm. Accessed 12 Mar 2020.
- [17] Ung COL. Community pharmacist in public health emergencies: quick to action against the coronavirus 2019-nCoV outbreak. Res Social Adm Pharm. 2020. https://doi.org/10.1016/j.sapharm.2020.02.003 (Epub ahead of print).